

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
17 February 2005 (17.02.2005)

PCT

(10) International Publication Number
WO 2005/014006 A1

(51) International Patent Classification⁷: **A61K 31/663**,
31/451, 31/495, 31/505, 31/506, A61P 19/00, 19/10,
35/00, 35/04

(74) Agent: **GRUBB, Philip**; Novartis AG, Corporate Intel-
lectual Property, CH-4002 Basel (CH).

(21) International Application Number:
PCT/EP2004/008107

(22) International Filing Date: 20 July 2004 (20.07.2004)

(25) Filing Language: English

(26) Publication Language: English

(81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD,
MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG,
PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM,
ZW.

(30) Priority Data:
60/488,925 21 July 2003 (21.07.2003) US

(84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI,
FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except AT, US*): **NO-
VARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel
(CH).

(71) Applicant (*for AT only*): **NOVARTIS PHARMA GMBH**
[AT/AT]; Brunner Strasse 59, A-1230 Vienna (AT).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): **ZIMMERMANN,
Johann** [DE/DE]; Oberdorfstrasse 8, 79424 Auggen (DE).
GOESSL, Carsten [DE/US]; 11 Cattano Avenue, Apt.412,
Morristown, NJ 07060 (US).

Published:

— with international search report

*For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.*

(54) Title: COMBINATIONS OF A CATHEPSIN K INHIBITOR AND A BISPHOSPHONATE IN THE TREATMENT OF BONE
METASTASIS, TUMOR GROWTH AND TUMOR-INDUCED BONE LOSS

(57) Abstract: This invention relates to pharmaceutical preparations comprising certain types of bisphosphonates and certain types
of Cathepsin K inhibitors, in particular in the prevention and treatment of bone metastases, tumor-induced hypercalcemia, tumor
growth, tumor-induced bone loss and bone loss diseases such as osteoporosis or cancer-therapy-induced bone loss.

WO 2005/014006 A1